Business
Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis
-- Data from the RLYB212 Phase 1b Proof-of-Concept Study to be Featured as an Oral Presentation at ISTH -- -- Company to Host Webcast Following ISTH Oral
About this update from Rallybio Corporation
[{"type":"text","content":"\n-- Data from the RLYB212 Phase 1b Proof-of-Concept Study to be Featured as an Oral Presentation at ISTH --\n\n\n -- Company to Host Webcast Following ISTH Oral Presentation of RLYB212 --\n\n\n NEW HAVEN, Conn.--(BUSINESS WIRE)--\nRallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that results from the RLYB212 Phase 1b proof-of-concept study will be presented at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28. RLYB212 is an anti-HPA-1a monoclonal antibody being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).\n\n\nData from the Phase 1b RLYB212 proof-of-concept study will be presented by Christof Geisen, M.D., as an oral presentation.\n\n\nDetails of the abstract presentation are as follows:\n\n\n\nTitle: Dose-Dependent Elimination of HPA-1a Platelets by Subcutaneous RLYB212, a Monoclonal Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia\n\n\n\nPresenting Author: Christof Geisen, M.D., Institute of Transfusion Medicine and Immunohaematology, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen gGmbH, Frankfurt am Main, Germany.\n\n\n\nAbstract Presentation Number: OC 02.1\n\n\n\nSession Title: Bleeding and Neonatal Alloimmune Thrombocytopenia in Pregnancy\n\n\n\nSession Date and Time: Saturday, June 24, 2023, from 13:00 - 14:15 (1:00 p.m. - 2:15 p.m. ET)\n\n\n\nPresentation Time: 13:00 - 13:15 (1:00 p.m. - 1:15 p.m. ET), 12-minute presentation and 3-minute Q&A\n\n\n\nThe abstract can be accessed via the official ISTH 2023 Congress website at: https://www.isth2023.org/\n\n\nInvestor and Analyst Meeting Webcast\n\n\nRallybio also announced today that the Company will host an investor and analyst meeting on Saturday, June 24, 2023 from 4:00 to 6:00 p.m. ET. Institutional investors and sell-side analysts are invited to attend in person. If you would like to attend in person, please contact Ami Bavishi at [email protected].\n\n\nThe meeting will include a presentation of the data from the RLYB212 Phase 1b Proof-Of-Concept Study by Dr. Geisen, and a corporate discussion on the RLYB212 development program...